BR112021022828A2 - Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração - Google Patents

Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração

Info

Publication number
BR112021022828A2
BR112021022828A2 BR112021022828A BR112021022828A BR112021022828A2 BR 112021022828 A2 BR112021022828 A2 BR 112021022828A2 BR 112021022828 A BR112021022828 A BR 112021022828A BR 112021022828 A BR112021022828 A BR 112021022828A BR 112021022828 A2 BR112021022828 A2 BR 112021022828A2
Authority
BR
Brazil
Prior art keywords
egfr
tyrosine kinase
kinase inhibitors
combination therapies
bispecific anti
Prior art date
Application number
BR112021022828A
Other languages
English (en)
Portuguese (pt)
Inventor
Matthew Lorenzi
Sheri Moores
Sylvie Laquerre
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
Publication of BR112021022828A2 publication Critical patent/BR112021022828A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021022828A 2019-05-14 2020-05-14 Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração BR112021022828A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112021022828A2 true BR112021022828A2 (pt) 2022-04-12

Family

ID=78716450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022828A BR112021022828A2 (pt) 2019-05-14 2020-05-14 Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração

Country Status (12)

Country Link
EP (1) EP3968985A4 (https=)
JP (2) JP2022531980A (https=)
KR (1) KR20220010731A (https=)
CN (1) CN113840601A (https=)
AU (1) AU2020275272A1 (https=)
BR (1) BR112021022828A2 (https=)
CA (1) CA3140360A1 (https=)
EA (1) EA202193117A1 (https=)
IL (1) IL287962A (https=)
MA (1) MA55978A (https=)
MX (1) MX2021013955A (https=)
SG (1) SG11202112412QA (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024346227A1 (en) * 2023-09-21 2026-04-09 Beijing Neox Biotech Limited Multi-specific antibodies and uses thereof
TW202519556A (zh) * 2023-09-28 2025-05-16 大陸商上海翰森生物醫藥科技有限公司 雙特異性抗體在製備治療癌症的藥物中的用途
CN120271706A (zh) * 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
RU2601892C2 (ru) * 2008-03-06 2016-11-10 Дженентек, Инк. Комбинированная терапия антагонистами с-мет и egfr
DK2560993T3 (da) * 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
SG11202108311RA (en) * 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies

Also Published As

Publication number Publication date
JP2022531980A (ja) 2022-07-12
EP3968985A1 (en) 2022-03-23
KR20220010731A (ko) 2022-01-26
SG11202112412QA (en) 2021-12-30
EA202193117A1 (ru) 2022-02-11
CA3140360A1 (en) 2020-11-19
AU2020275272A1 (en) 2021-12-02
MA55978A (fr) 2022-03-23
JP2025118606A (ja) 2025-08-13
IL287962A (en) 2022-01-01
EP3968985A4 (en) 2023-07-26
MX2021013955A (es) 2022-03-11
CN113840601A (zh) 2021-12-24

Similar Documents

Publication Publication Date Title
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
PH12021552030A1 (en) Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
PH12020550055A1 (en) Antibodies that bind egfr and cmet
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
BR112017023943A2 (pt) anticorpos heterodimêricos que ligam cd3 e antígenos de tumor
EA201890028A1 (ru) Антитело, связывающее cd3 человека
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
CL2020002103A1 (es) Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139)
BR112021022828A2 (pt) Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração
BR112016000903A2 (pt) anticorpos
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2
EP4420727A3 (en) Bispecific egfr/c-met antibodies
CR20160199A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
MX2021015882A (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
MX2019005858A (es) Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo.
PE20230381A1 (es) Proteina de union a rgma
CL2015001939A1 (es) Nuevos fragmentos de anticuerpos, composiciones y sus usos.
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
MX2020014104A (es) Combinaciones de poziotinib con un anticuerpo anti-her1, her2 o her4 y sus metodos de uso.
EA201992825A1 (ru) Трехкомпонентные комбинированные препараты антител